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Objectives:  A  10-year  retrospective  study  investigated  factors  for survival  and  laryngeal  preservation  in
advanced  laryngeal,  hypopharyngeal  or  epilaryngeal  neoplasia.
Material  and method:  Two  hundred  and  forty-six  patients  with  advanced  cancer  of  the  larynx  (17.48%),
hypopharynx  (48.78%)  or  epilarynx  (33.74%)  undergoing  primary  organ-sparing  treatment  were  included
from 1998  to  2008.  Treatment  comprised  chemotherapy  followed  by  radiation  therapy  for  92.68%  of
patients,  isolated  radiation  therapy  for 1.6%  and  concomitant  or  sequential  radiation-chemotherapy  for
5.7%. General  health  status,  history  and  tumor  status  were  recorded.  Factors  inﬂuencing  survival  were
analyzed  by  Kaplan-Meier  estimator,  log-rank  test  and  Cox  models.
Results:  Median  overall  survival  of  the  population  was  2.3  years  and  median  laryngeal  preservation
0.99  years  in  male  patients  and  2 years  in  female  patients.  Survival  correlated  signiﬁcantly  with  body
mass  index  (BMI;  P = 0.0004),  WHO  performance  status  (P  =  0.0064),  alcohol  consumption  (P  =  0.0004)
and  cessation  (P <  0.0001)  and  also T stage  (P =  0.0038),  initial  laryngeal  mobility  (P =  0.0002)  and  post-
chemotherapy  assessment  (P < 0.0001).  Survival  with  functional  larynx  correlated  with  baseline  BMI  at
ﬁrst consultation  (P =  0.016),  baseline  WHO  grade  (P =  0.0005),  laryngeal  mobility  (P  < 0.0001),  T staging
(P  =  0.0009),  and  T and/or  N chemotherapy  response  to a classical  organ  preservation  protocol  (P <  0.0001).
Conclusion:  Over  and  above  established  criteria,  the  present  study  highlighted  the  importance  of  general
health  and  nutritional  status  during  treatment.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Until the early 1990s, surgery was the main treatment for
dvanced squamous cell carcinoma of the larynx and hypopharynx.
lternatives to this mutilating therapy emerged with the devel-
pment of “laryngeal preservation” protocols based on radiation
herapy, in isolation or association with neoadjuvant, concomitant
r alternating chemotherapy. They were ﬁrst studied in ran-
omized controlled trials (GETTEC, GORTEC, EORTC, etc.) [1,2],
omparing them ﬁrst with surgery and then to one another, and
emonstrating that they allowed preservation of the larynx with-
ut impairing survival.
∗ Corresponding author.
E-mail address: cuny-f@chu-caen.fr (F. Cuny).
http://dx.doi.org/10.1016/j.anorl.2015.03.007
879-7296/© 2015 Elsevier Masson SAS. All rights reserved.The present study analyzed outcomes for organ preservation
therapy and factors for overall and recurrence-free survival.
2. Materials and method
2.1. Population
Patients were selected via the Lower Normandy Cancer Reg-
istry and treated in the Caen University Hospital Center or in the
Franc¸ ois Baclesse Cancer Care Center in Caen (France). Cases of
advanced laryngeal, epilaryngeal or hypopharyngeal cancer diag-
nosed between January 1, 1998 and December 31, 2008 were
eligible for inclusion.
None of the patients had previous history of cancer in the
anatomic regions concerned by the study.
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Presenting symptoms were dysphagia in 99 patients (40.24%),
dysphonia in 61 (24.80%), local or referred pain (otalgia) in 3630 F. Cuny et al. / European Annals of Otorhinolary
.2. Data analysis
Overall survival, recurrence-free survival and survival with
aryngeal preservation were studied according to various criteria.
Study variables comprised:
demographic data: age ≤ or >70 years; gender;
non-laryngeal oncological history, if any; familial history of neo-
plasia;
laryngeal risk factors: chronic laryngitis, laryngeal papillomato-
sis, alcohol abuse and smoking and failure to cease after
diagnosis;
clinical factors: weight, height, body mass index (BMI), date of
diagnosis, comorbidities (cardiovascular risk factors, pulmonary
history, hepato-gastroenterological history), WHO  grade at diag-
nosis (World Health Organization performance status, from 0 to
4, with 0 corresponding to normal activity without restriction and
4 to incapacity to look after oneself or permanently bedridden or
conﬁned to a chair), presenting symptomatology;
tumoral factors: location, TNM stage (2009 revised Union for
International Cancer Control [UICC] classiﬁcation), histology;
treatment criteria: type of treatment, time to treatment (inter-
val between ﬁrst specialist ENT consultation and treatment
initiation); in case of radiation therapy and/or chemotherapy,
proportion (percentage of Grays) of planned treatment ﬁnally
administered, chemotherapy dose and response quality.
Indications were determined by multidisciplinary team meet-
ng. All patients underwent primary laryngeal preservation therapy
isolated radiation therapy or organ preservation protocol). Some
reatment choices were determined by tumor location (e.g., in
etro-cricoarytenoid T2 lesion, radiation therapy might be pro-
osed in the multidisciplinary team meeting).
Treatment according to tumor stage was as follows:
in T2 tumor: radiation therapy;
in T3 tumor: organ preservation was preferred, using the Al-
Sarraf protocol [3] or, after 2006, the TREMPLIN protocol [4].
Response was analyzed after the 3 chemotherapy courses, by
clinical assessment (including endoscopy, not systematically
under general anesthesia) and radiologic assessment by contrast-
enhanced cervicothoracic CT scan, distinguishing responders and
non-responders: patients with >50% reduction in tumor size and
mobile larynx were considered good responders and went on to
complementary radiation therapy, while non-responders under-
went total (pharyngo)-laryngectomy.
Induction chemotherapy on the Al-Sarraf protocol comprised
00 mg/m2 cisplatin on D1 and 1 g/m2 5-ﬂuorouracil (5FU) on D1-
5, repeated 3 times at 21-day intervals. In 10 patients (0.04%),
arboplatin replaced cisplatin due to contraindications (kidney
nvolvement, hearing loss) or fragility (cardiovascular risk factors
ulmonary, history, hepato-gastroenterological history). In 2006,
axotere was added to the organ preservation protocols. In the
REMPLIN protocol, induction chemotherapy comprised 75 mg/m2
ocetaxel administered by 1-hour intravenous (IV) perfusion on D1
f each course, followed by 75 mg/m2 cisplatin by 1-hour IV per-
usion on D1 and by 750 mg/m2/day 5FU by continuous perfusion
rom D1 to D5, repeated 3 times at 3-week intervals. Patients with
trong response (>50% reduction in tumor size and mobile larynx)
nderwent external radiation therapy after an interval of between and 6 weeks, with fractionated 3D conformal delivery of a total
0 Gy in 35 2-Gy per session fractions with 5 sessions per week. The
ssociated chemotherapy was either 100 mg/m2 cisplatin (arm A)
n 1-hour IV perfusion on days 1, 22 and 43 of the radiation therapy,y, Head and Neck diseases 132 (2015) 129–134
or 400 mg/m2 cetuximab (arm B) in 2-hour IV perfusion on D1 then
250 mg/m2 in 1-hour IV perfusion on days 8, 15, 22, 29, 36 and 43.
Patients with T4a tumor received an organ preservation protocol
at the time of study; this attitude is now obsolete and T4a tumor is
managed by ﬁrst-line surgery.
Results were assessed at short and medium terms (3, 24, 36 and
60 months), comprising:
• locoregional and remote oncologic control;
• rate and treatment of recurrence;
• mortality: date and cause of death, with oncologic and functional
status at that date;
• functional results (laryngeal preservation): swallowing (enteral
feeding or not) and respiration (tracheotomy or not). Preserved
laryngeal function was  deﬁned by absence of feeding tube or
tracheotomy cannula.
2.3. Statistical analysis
For qualitative variables, descriptive analysis provided frequen-
cies with exact 95% conﬁdence intervals. For quantitative variables,
means, standard deviations, medians and quartile ranges were
studied. Correlations between baseline variables and laryngeal
preservation (less than 3 months after end of treatment) were
assessed on 2 or Fisher test. Univariate analysis of survival fac-
tors used the Kaplan-Meier estimator and log-rank test. Variables
associated with P < 0.10 were introduced stepwise in a multivariate
Cox model.
The signiﬁcance threshold was  set at P < 0.05. Analysis was per-
formed on SAS software (version 9.2; SAS Institute Inc., Cary, NC,
USA).
3. Results
3.1. Demographic variables
Two hundred and forty-six patients were included, with 232
males (94.31%). Mean age at diagnosis was  59.75 years, with a
median of 59.21 years (range, 36-81 years).
3.2. History
Only 5 patients had familial history of head and neck cancer.
Fourteen had an epidemiologically linked synchronous cancer: 4 of
the esophagus, 2 of the lung and 8 of the upper airway.
3.3. Risk factors
Two hundred and thirty patients (93.50%) were chronic smok-
ers, with a mean 43 pack-years (PY) (range, 7-120 PY). Two  hundred
and two  (82.11%) showed alcohol abuse. Both risk factors were
concomitantly present in 194 patients (78.86%).
3.4. Clinical factors
Half of the included patients (50.40%) were free of comorbidity.
Two hundred and thirty-seven patients (96.34%) had WHO
scores of 0 or 1. Mean BMI  was 24.21 kg/m2.(14.63%) and cervical adenopathy in 27 (10.98%). Cancer had been
revealed by dyspnea in 16 patients (6.50%) and by hemoptysis in 3
(1.22%); diagnosis was serendipitous, without clinical signs, in only
4 cases (1.83%).
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Table  1
Tumor and lymph node staging in organ preservation protocol patients.
T/N N0 (%) N1 (%) N2 (%) N3 (%) Total (%)
T2 8 (3.25) 7 (2.85) 15 (6.10) 3 (1.22) 33 (13.41)
T3  78 (31.70) 56 (22.76) 39 (15.85) 5 (2.03) 178 (72.36)
T4  7 (2.86) 5 (2.03) 21 (8.54) 2 (0.81) 35 (14.23)
Total 93 (37.81) 68 (27.64) 75 (30.49) 10 (4.06) 246 (100)
Table 2
Chemotherapy response.
T assessment Percentage
No response 4.07
<50% 6.33
>50%, immobile larynx 10.41
>50%, mobile larynx 16.29
>80% 30.77
Complete 29.41
Progression 2.71
N  assessment Percentage
No response 4.52
<50% 11.31
>50% 13.12
>80% 9.95
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1.53 years (range, 1.36-1.83 years).Complete 56.56
Progression 4.52
.5. Tumor factors
Tumor location targeted 3 anatomic regions: larynx (17.48% of
ases), hypopharynx (48.78%) and epilarynx (33.74%).
All patients have squamous cell carcinoma (well-differentiated,
4.15%; non-differentiated, <5%).
Table 1 shows tumor distribution according to 2002 UICC TNM
taging.
.6. Treatment
Mean time to treatment was 25 days. One hundred and seventy-
wo patients (69.92%) had complete uninterrupted treatment; in 74
30.08%), treatment was interrupted for poor tolerance.
Adverse chemotherapy effects were principally:
hematologic (43.21%): neutropenia, thrombopenia;
digestive (7.82%): vomiting, nausea, diarrhea;
renal (4.53%).
Rarer side effects were cardiologic (1.65%) or ENT (hearing loss
n 0.41% of cases). In 41.56% of cases, there were no complications.
In radiation therapy, 71.54% of patients experienced no major
grade III or IV) adverse events. Poor tolerance was  mainly due to
ocal radiation-induced pain.
Ten patients died during primary chemo- and/or radiation ther-
py.
.7. Oncologic response
.7.1. Chemotherapy
Three-quarters of patients showed signiﬁcant tumor regression
>50% reduction, with mobile larynx; Table 2).
.8. Functional results.8.1. Laryngeal preservation
One hundred and forty-ﬁve patients (59%) had preserved laryn-
eal function at 3 months after the end of primary treatmenty, Head and Neck diseases 132 (2015) 129–134 131
(chemo- and radiation therapy). Thirteen of the patients without
early phase (<3 months) functional larynx died, including 10 from
chemotherapy-related causes, and 7 underwent laryngectomy dur-
ing primary treatment due to chemotherapy failure.
Three months after the end of chemo- and radiation ther-
apy, 30 patients underwent laryngectomy. At 2 years, 97 patients
(39.5%) had a preserved larynx, 91.5% of which were functional
(89 patients). At 3 years, 26 patients (27%) were alive with pre-
served laryngeal function. Median laryngeal preservation was 0.99
years (range, 0.75-1.35 years) in male patients and 2 years (range,
0.30-3.67 years) in females.
Various factors were signiﬁcantly associated with laryngeal
preservation:
• baseline laryngeal mobility correlated with immediate (<3
months) laryngeal preservation (P = 0.0081);
• non-invasion of the pre-epiglottic space (P = 0.0332) or paraglot-
tic space correlated with laryngeal preservation (P = 0.0212);
• complete treatment correlated with laryngeal preservation
(P > 0.0001);
• WHO  general health status grade 0 or 1 at ﬁrst consultation
showed a correlation with laryngeal preservation just at the limit
of signiﬁcance (P = 0.0493).
Tumor differentiation, on the other hand, was  not signiﬁcantly
related to laryngeal preservation (P = 0.2559).
3.9. Survival
3.9.1. Overall survival
One hundred and seventy-eight of the 246 patients (72.35%)
died and 11 (4.4%) were lost to follow-up. Only a quarter (23.25%)
was alive at last follow-up. Ten died of treatment-related compli-
cations.
Median overall survival in the population as a whole was 2.28
years (range, 1.44-12.57 years), and 2.16 years (range, 1.73-2.83
years) in male patients and 6.48 years (range, 1.44-12.57 years) in
females. Three- and 5-year survivals could not be analyzed, due to
heterogeneity of follow-up and small numbers of survivors at these
time-points.
Clinical factors favoring overall survival were:
• BMI  ≥25 kg/m2 (HR < 1; P = 0.0345; Fig. 1A);
• alcohol intake <30 g/d (P = 0.0104).
Factors impairing overall survival were:
• WHO grade >1 (HR > 1; P = 0.0044; Fig. 2A);
• tumoral factors such as TNM stage T2, T3 or T4 (P = 0.0038;
Fig. 2B), and laryngeal immobility (P = 0.0001 comparing over-
all survival in patients with immobile larynx versus mobile
larynx or larynx with reduced mobility); tumor stage T >2 nega-
tively impacted overall survival (T3: HR > 1, P = 0.0051; T4: HR > 1,
P = 0.0092), as did lymph node stage >N0 (HR > 1; P = 0.0229);
• emergency tracheotomy (P = 0.0075) and lymph node cap-
sule rupture (P = 0.0186) found on neck dissection signiﬁcantly
reduced overall survival.
3.9.2. Recurrence-free survival
Median recurrence-free survival in the study population wasFactors favoring recurrence-free survival were:
• BMI  (P = 0.0005): BMI  ≥25 kg/m2 emerged as a protective factor
(P = 0.0279);
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lig. 1. Overall survival. A. Overall survival according to BMI. B. Overall survival
ccording to alcohol intake.
glottic mobility on endoscopy following organ preservation
(P = 0.0008);
WHO  grade 0 or 1 (P = 0.0025);
no emergency tracheotomy (P = 0.0002);
chemotherapy response (>50% tumor reduction on T and N stag-
ing) in T and N organ preservation protocols (P < 0.0001).
Factors impairing recurrence-free survival were:
alcohol consumption (P = 0.0025): alcohol intake >30 g/d reduced
recurrence-free survival (P = 0.0080);
advanced T (P = 0.046) and N stage (P = 0.0371);
emergency management (P = 0.075).
. Discussion
The present study found a median overall survival of 6.5 years
range, 1.4-12.6 years). Other French teams reported lower rates,
etween 3.9 years and 19.3 months [5,6].
.1. Factors inﬂuencing survivalFactors inﬂuencing survival in the present series were base-
ine BMI, alcohol consumption, WHO  grade at ﬁrst consultation,
aryngeal mobility, tumor T stage, induction response, emergencyFig. 2. Overall survival. A. Overall survival according to WHO  grade. B. Overall sur-
vival according to tumor stage.
tracheotomy and lymph node capsule rupture on neck dissec-
tion. Cox model analysis identiﬁed two protective factors: BMI
>25 kg/m2 and WHO  grade 0; two factors impaired survival:
advanced tumor stage (T3 or T4) and adenopathy.
Arzul [5] reported only initial treatment response as affecting
overall survival. Gamby [6] found an impact of ASA (American
Society of Anesthesiologists) score and of histologic type (better
survival in moderately or poorly differentiated tumor). Spaulding
et al. [7] found better induction response in moderately differenti-
ated tumor. Similar tumor staging results to the present have been
reported in several studies [8–10].
The role of BMI  has been analyzed in various tumor locations.
High BMI  is a risk factor for onset of neoplasia in digestive cancer
(colon) [11] but may  have a protective role in upper aerodigestive
tract cancer [12]. Low BMI  is a risk factor for head and neck cancer
[13]. These results, however, are to be taken with caution, as various
deﬁciencies (in iron and vitamin A and C) play a role in onset of head
and neck cancer [14].
4.2. Inﬂuence of treatment on survival
The present study found no inﬂuence of treatment on survival.
However, a change in chemotherapy protocol during the study
period (cisplatin-5FU until 2006, then cisplatin-5FU-taxotere) pre-
vented statistical demonstration. Most of the present patients
(92.68%) received induction chemotherapy. Only 1.63% received
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solated radiation therapy, and 5.69% concomitant or alternating
adio-chemotherapy.
Several retrospective studies reported no difference in overall
urvival between radical surgery plus radiation therapy and non-
perative treatment [1,15,16]. Richard et al. [17] reported lower
urvival with induction chemotherapy.
Non-operative attitudes were compared in the MACH-NC meta-
nalysis [18]. Adding platinum-based chemotherapy improved
urvival by 4%, with a gain of 3% associated with concomitant radio-
hemotherapy versus induction chemotherapy. The contribution
o organ preservation of cetuximab associated to radiation therapy
emained to be proven.
The TREMPLIN study [19], comparing radiation therapy plus
ither platins or cetuximab after taxotere-platin-5ﬂurouracile
hemotherapy, found no signiﬁcant difference in survival, but
ewer hematologic or renal side effects with cetuximab.
Induction chemotherapy associated to radiation therapy and
adical surgery showed comparable overall survival [1,15,16].
adio-chemotherapy showed slightly but non-signiﬁcantly better
esults, but greater toxicity [18].
Regarding laryngeal preservation therapies for stage III or
V glottic and subglottic cancer, Forastiere et al. [20] compared
nduction by cisplatin-ﬂuorouracil followed by radiation therapy,
oncomitant radio-chemotherapy with cisplatin, and isolated radi-
tion therapy. Taking all treatments together, median survival was
0.8 years, and did not signiﬁcantly differ according to treatment,
lthough concomitant radio-chemotherapy was  associated with
oorer survival than induction chemotherapy followed by radiation
herapy (P = 0.8).
In T4a laryngeal tumor, Francis et al. [21] studied overall and
ecurrence-free survival in 108 patients managed by ﬁrst-line total
aryngectomy. At 2 years, overall and recurrence-free survivals
ere respectively 81.3 and 78%; and both 60% at 5 years. Analyzing
he literature, they found 5-year overall survival ranging from 0 to
5% for radiation therapy, from 16 to 50.4% for concomitant radio-
hemotherapy and from 10 to 80.9% for surgery. Primary surgery
as associated with better survival in T4a laryngeal cancer.
.3. Laryngeal preservation
The present results for laryngeal preservation were poorer than
hose in the literature. In a study of veterans [15], the rate of laryn-
eal preservation at 2.8 years was 64%. In the GETTEC study, 42% of
atients had a functional larynx at 8.3 years [17].
The RTOG 91-11 [20] study reported 70% laryngeal preser-
ation with isolated radiation therapy, 72% with sequential
adiation-chemotherapy and 88% with concomitant radiation-
hemotherapy; 23% of patients managed by concomitant radiation-
hemotherapy were restricted to liquid feeding and 3% were totally
phagic. In hypopharyngeal cancer, the EORTC study [1] found a
ate of in situ larynx (without tumor, tracheotomy or enteral feed-
ng) of 42% at 3 years and 35% at 5 years. The present poorer results
ay  be due to differences in population, the present series includ-
ng a higher rate of cartilage involvement (13.41%).
Likewise, Forastiere et al. [20] reported that concomitant
adiation-chemotherapy was associated with a signiﬁcantly higher
ate of laryngeal preservation than induction chemotherapy fol-
owed by radiation therapy (P = 0.0050) or isolated radiation
herapy (P < 0.001). The three laryngeal preservation protocols
howed no difference in long-term side effects [20].
The present study highlighted the inﬂuence on laryngeal preser-
ation of general health status, laryngeal mobility, pre-epiglottic
r paraglottic space invasion, any sequential therapy, and good
reatment response.
Janot et al. [2] reported arytenoid mobility as a factor of preser-
ation of laryngeal function: 51% with mobile versus 18% withy, Head and Neck diseases 132 (2015) 129–134 133
immobile arytenoid. Staton et al. [22] likewise highlighted cartilage
invasion, T4 tumor and pulmonary history as predictive factors for
poor functional results.
5. Conclusion
The natural evolution of laryngeal cancer, combined to muti-
lating therapies, can induce temporary or deﬁnitive sequelae and
functional disability: impairment or loss of the physiological voice,
swallowing and respiratory disorder, olfactory disorder, pharyn-
geal stenosis and radiation-induced pain [23]. Babin and Grandazzi
point out that the psychological and social consequences can be
severe [24].
Organ preservation protocols spare laryngeal function without
impairing survival. When laryngeal function is thus preserved, the
quality of patients’ social relations is enhanced.
The advent in research studies of new molecules targeting tumor
receptors (cetuximab) holds out hope for improved results in terms
of survival and laryngeal preservation (GORTEC study 2007-02).
These therapeutic trials aim to deﬁne laryngo-esophageal preser-
vation. Vickery et al. [25] stressed the need to regulate these new
protocols to maximize the chances of patients, in whom indications
for radical surgery may  be postponed. Nevertheless, the results
reported by Francis et al. [21] encourage patient selection, not
reducing total laryngectomy to salvage status.
The present study conﬁrmed the inﬂuence of prognostic factors
on overall and functional survival: alcohol consumption and smok-
ing, and good response to primary treatment. It further highlighted
the novel role of body mass index. Nutritional care in head and
neck cancer should be optimal and multidisciplinary, beginning in
the ﬁrst consultation.
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